A new drug combination from Vaccibody and Roche may help to treat patients with cervical cancer.

New collaboration aims to treat cervical cancer

Hands cradling female reproductive system

The companies Vaccibody and Roche have started a new collaboration to investigate a drug combination to treat patients with advanced cervical cancer.

 

Both companies are members of Oslo Cancer Cluster and are involved in the development of novel cancer treatments.

Martin Bonde, CEO of Vaccibody, said: “We are very pleased with this collaboration. This is an important study as it explores a novel targeted treatment approach that addresses the high medical need of patients with advanced cervical cancer.”

 

Cervical cancer is the most commonly occurring cancer among women in developing countries and is the second most commonly occurring cancer amongst women worldwide.

 

Vaccibody is a vaccine company that aims to develop and discover new immunotherapies to treat difficult forms of cancer. They have developed a therapeutic DNA vaccine that treats cancers caused by HPV (the human papillomavirus).

 

Cervical cancer is caused by high risk HPV. HPV16 is the type that most frequently causes cancer.

 

Immunotherapy is a type of cancer treatment that aims to switch on a patient’s immune system to kill cancer cells.

 

Roche is a healthcare company that has developed an immune-checkpoint inhibitor. Now Vaccibody wants to test their vaccine in combination with the immune-checkpoint inhibitor designed by Roche.

 

An immune checkpoint inhibitor is a type of drug that blocks certain proteins made by some types of cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better.

 

Agnete Fredriksen, President and CSO of Vaccibody, said that the combination of the two drugs build on the positive results seen when their vaccine has been used on patients with cervical cancer. Therefore they now expect to see positive results when they combine the vaccine with an immune checkpoint inhibitor.

 

During the second half of 2019, Vaccibody expects to begin the phase II study, which will involve 50 patients. It will assess the safety of the drug, its ability to invoke a response in the immune system, how the patients tolerate it and how efficient the drug is. The group for this new drug combination involves patients with advanced cervical cancer.

 

Raised NOK 230 million

Vaccibody also raised NOK 230 million (EUR 23.6 Million) in a private placement the same week. The sum was indeed placed all within one day, according to Agnete Fredriksen.

The proceeds from the share sales will be used to conduct the phase II clinical study of the drug combination from Vaccibody and Roche. The money will also go to the preparation of expansion patient groups in Vaccibody’s clinical trials and to generate corporate purposes.

 

For more information, read the press release from Vaccibody.

 

 

Roche Medicine Ready to Fight Breast Cancer

On the 15th of August, drug Kadycla (trastuzumab emtansin) is finally approved by the Beslutningsforum and ready to help hundreds with breast cancer in Norway.

The drug, developed by company Roche, specifically targets patients with the variant HER2 positive breast cancer – a breast cancer that tests positive for human epidermal growth factor receptor 2, a protein which promotes growth of cancer cells.

About 15-20% of cases in breast cancer, cancer cells have a gene mutation that produces excess HER2 protein, thusly making it a more aggressive form of breast cancer as well as being resistant to hormone therapy. However, treatments that specifically target HER2 are very effective.

New Drug Kadycla
This is where newly developed drug Kadycla comes in.

Kadycla is the first medicine targeted towards breast cancer patients where the cell lymph nodes are linked to the targeted antibody; meaning it’s the first drug where lymph nodes, or parts of the cell that filter out cancer, are linked to the antibody that attacks or even neutralizes the infected cell. This causes the chemo to target the HER2 positive cancer cells.

Prolonged Survival Rate
With the drugs approval, around one hundred Norwegian cancer patients are provided with a treatment program that shows a median prolonged survival rate of 5,8 months, compared to the combination of lapatinib and kapecitabine for persons with the variant HER2-positive breast cancer.

Better Quality of Life
On top of this, it’s known that spreading breast cancer is a deadly disease with lower quality of life, but Kadycla helps by attacking cancer cells in place of the body’s own healthy cells. Essentially, this means better quality of life for the patient due to fewer symptoms brought on by the disease.

Reached an Agreeable Solution
Kadycla, since September in 2014, has been recommended in the Norwegian Breast Cancer Group’s medical guidelines for those who would benefit from its capabilities. Roche, in this case, through the span of three years aligned eight different pricing options for the authorities. In regards to this, Audun Ohna, director of market access and pricing, comments:

– We have worked a long time so that Norwegian breast cancer patients can have the chance to use Kadycla in Norwegian health services. After roughly three years negotiating, where we have stretched ourselves thin both economically and in variating payment solutions, we can finally and gladly say we have reached a solution that is both acceptable for both parties. This will benefit patients, doctors and society as a whole.